Charles Schwab Investment Management Inc Phathom Pharmaceuticals, Inc. Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 292,860 shares of PHAT stock, worth $2.62 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

292,860

Previous 285,870 2.45%

Holding current value

$2.62 Million

Previous $2.94 Million 79.82%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$10.25 - $19.5 $71,647 - $136,305	6,990 Added 2.45%	292,860 $5.29 Million
Q2 2024 Aug 12, 2024	BUY	$8.97 - $12.05 $191,742 - $257,580	21,376 Added 8.08%	285,870 $2.94 Million
Q1 2024 May 08, 2024	BUY	$6.21 - $11.05 $12,233 - $21,768	1,970 Added 0.75%	264,494 $2.81 Million
Q4 2023 Feb 06, 2024	BUY	$6.99 - $10.71 $110,742 - $169,678	15,843 Added 6.42%	262,524 $2.4 Million
Q3 2023 Nov 08, 2023	BUY	$10.26 - $15.7 $695,740 - $1.06 Million	67,811 Added 37.91%	246,681 $2.56 Million
Q2 2023 Aug 09, 2023	BUY	$7.28 - $14.32 $52,874 - $104,006	7,263 Added 4.23%	178,870 $2.56 Million
Q1 2023 May 11, 2023	SELL	$6.19 - $12.36 $10,194 - $20,356	-1,647 Reduced 0.95%	171,607 $1.23 Million
Q4 2022 Feb 13, 2023	BUY	$9.18 - $11.53 $152,149 - $191,098	16,574 Added 10.58%	173,254 $1.94 Million
Q3 2022 Nov 14, 2022	BUY	$6.46 - $12.11 $238,154 - $446,447	36,866 Added 30.77%	156,680 $1.74 Million
Q2 2022 Aug 15, 2022	SELL	$6.2 - $15.5 $39,512 - $98,781	-6,373 Reduced 5.05%	119,814 $1.01 Million
Q1 2022 May 13, 2022	BUY	$11.55 - $20.06 $33,356 - $57,933	2,888 Added 2.34%	126,187 $1.72 Million
Q4 2021 Feb 11, 2022	BUY	$17.83 - $33.15 $43,291 - $80,488	2,428 Added 2.01%	123,299 $2.43 Million
Q3 2021 Nov 16, 2021	BUY	$30.69 - $36.83 $422,018 - $506,449	13,751 Added 12.84%	120,871 $3.88 Million
Q2 2021 Aug 16, 2021	BUY	$32.66 - $39.87 $648,758 - $791,977	19,864 Added 22.77%	107,120 $3.63 Million
Q1 2021 May 17, 2021	BUY	$33.86 - $48.68 $384,581 - $552,907	11,358 Added 14.96%	87,256 $3.28 Million
Q4 2020 Feb 16, 2021	BUY	$33.22 - $50.26 $3,687 - $5,578	111 Added 0.15%	75,898 $2.52 Million
Q3 2020 Nov 13, 2020	SELL	$29.24 - $40.19 $171,960 - $236,357	-5,881 Reduced 7.2%	75,787 $2.78 Million
Q2 2020 Aug 14, 2020	BUY	$25.06 - $54.6 $327,408 - $713,349	13,065 Added 19.04%	81,668 $2.69 Million
Q1 2020 May 15, 2020	BUY	$24.65 - $42.83 $20,114 - $34,949	816 Added 1.2%	68,603 $1.77 Million
Q4 2019 Feb 07, 2020	BUY	$18.59 - $37.67 $1.26 Million - $2.55 Million	67,787 New	67,787 $2.11 Million

Others Institutions Holding PHAT

# of Institutions

144

Shares Held

73.6M

Call Options Held

42.3K

Put Options Held

45.7K

View Full List

About Phathom Pharmaceuticals, Inc.

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $350M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

More about PHAT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Phathom Pharmaceuticals, Inc. Transaction History